1. Edmonston TB, Gibori H, Kushnir M, et al. New microRNA-based diagnostic test for lung cancer classification. ASCO 2011
2. Edmonston TB, Kushnir M, Lithwick Yanai G, et al. microRNAs as clinical biomarkers for lung cancer classification. AACR 2011
3. Basic Information 

1. Arnon Afek, Kinneret Rosenblatt, Hila Tabibian-Keissar, Merav Zepeniuk, Lahav Cohen, Harel Dan, Orit Zion, Yulia Strenov, Sylvie Polak-Charcon and Marina Perelman. MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathology Research and Practice, online publication, 28 April 2010 (doi:10.1016/j.prp2010.03.005)
2. Meiri E, Spector Y, Cohen L, et al. MicroRNAs as powerful diagnostic tools for the differential diagnosis of lung tumors. Presented at: 44th American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2008; Chicago, IL. Abstract 11112.
3. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26(4):462-469.
4. Rosenwald S, Meiri E, Gilad S, et al. MicroRNA signature identifies tissue origin of primary and metastatic tumors. Presented at: 44th American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2008; Chicago, IL. Abstract 11028.
5. Liang Y. An expression meta-analysis of predicted microRNA targets identifies a diagnostic signature for lung cancer. BMC Med Genomics. 2008;1:61.
6. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008;54(10):1696-1704.

1. Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004;96(14):1105-1107.
2. Stang A, Pohlabeln H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.

1. Hammar SP. Immunohistology of lung and pleural neoplasms. In: Dabbs D, ed. Diagnostic Immunohistochemistry. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2006:329-403.
2. Camilo R, Capelozzi VL, Siqueira SA, Del Carlo Bernardi F. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2006;37:542-546.
3. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gärtner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003;443:122-132.
4. Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006;19(3):417-428.
5. Au NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol. 2004;12(3):240-247.
6. Saad RS, Liu YL, Han H, Landreneau RJ, Silverman JF. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol. 2004;35(1):3-7.
7. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol. 2002;55(9):662-668.
8. Tan D, Li Q, Deeb G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol. 2003;34(6):597-604.